Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids.

This study investigated whether thymosin beta 4 (Tβ4), encoded by the gene TMSB4X, plays a role in Alzheimer's disease (AD) pathology and could serve as a potential intervention target. Researchers generated cerebral organoids ("mini-brains") from induced pluripotent stem cells (iPSCs) carrying familial AD (fAD)-associated mutations in the amyloid precursor protein (APP) gene. Using these organoids, they characterized dynamic changes in cellular states and found that mature neuron formation was markedly reduced in fAD organoids compared to healthy controls, alongside increased cellular senescence and beta-amyloid (Aβ) production. Notably, TMSB4X/Tβ4 expression was significantly decreased both in fAD organoid neurons and in excitatory neurons from post-mortem AD patient brain data. Treatment with Tβ4 protein appeared to rescue neurodevelopmental deficits and reduce Aβ formation in the fAD organoids. Corroborating findings were also reported in 5xFAD transgenic mice. The study concludes that Tβ4 may act as a neuroprotective factor capable of mitigating altered neurogenesis and AD pathology. Key limitations include the use of organoid and animal models rather than human clinical data, and the inherent complexity of translating organoid findings to human disease.

Why this grade: Evidence is derived from iPSC-derived human brain organoids and 5xFAD transgenic mice, with no direct human clinical trial data, placing it in the preclinical-mixed category despite use of human-derived cellular models.